Share on LinkedInShare on LinkedIn

ARTICLE · 23 JUNE 2021

The CAT's Latest Paroxetine "Pay-For-Delay" Judgment: Market Definition Confusion

Bristows LLP
Bristows LLP
Contributor
Bristows LLP

Bristows LLP

We are Bristows, the world’s leading specialist law firm for clients that innovate. We are a London...

View firm profile
Explore more from Bristows LLP

The 10 May 2021 supplementary judgment of the Competition Appeal Tribunal (CAT) in the Paroxetine case upholds the EU approach to so-called ‘pay-for-delay'...

European UnionAntitrust/Competition Law

The 10 May 2021 supplementary judgment of the Competition Appeal Tribunal (CAT) in the Paroxetine case upholds the EU approach to so-called 'pay-for-delay' patent settlements as well as confirming the 2016 infringement decision reached by the Competition and Markets Authority (CMA). It also reduces the fines imposed on the parties.

However, the main point of interest may be the unusual approach the judgment adopts to market definition. It seems that the only way to make sense of the judgment on this point is to recognise that the CAT is adopting a different legal test to determine the relevant market before and after the point at which generic competitors are preparing to enter the market. In the view of the authors, that makes little legal or economic sense. It does however allow the CAT to respect EU case law while upholding the original decision of the CMA. In effect, a questionable approach to patent settlements seems to have led to a questionable approach to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from